Biased Ligands. Better Drugs.

TRV027 - AT1R Biased Ligand for Acute Heart Failure

Target Indication Lead
Optimization
Preclinical
Development
Phase
1
Phase
2
Phase
3
OwnershipCollaborator
TRV027 Angiotensin II type 1 receptor Acute Heart Failure intravenous Actavis
TRV130 Mu-opioid
receptor
Postoperative
Pain
intravenous Trevena Logo
TRV734 Mu-opioid
receptor
Moderate to
Severe Pain
oral Trevena Logo
Delta
Opioid
Delta-opioid
receptor
CNS   Actavis

TRV027 is an intravenous drug for the treatment of acute heart failure (AHF) in combination with standard diuretic therapy, and is currently being investigated in a Phase 2 clinical trial. TRV027 is a β-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R). Forest Laboratories Inc. (NYSE:FRX) has an exclusive option to license TRV027.

View TRV027 Publications

Copyright © Trevena, Inc.